Shield Therapeutics plc
OTC: SHIEF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Anders Lundstrom
- Employees
- 63
- Headquarters
- Gateshead, United Kingdom
- IPO year
- 2019
- Market cap
- $85.6M
- Website
- https://www.shieldtherapeutics.com
Loading SHIEF…
Loading profile data…Frequently asked questions about SHIEF
What does Shield Therapeutics plc (SHIEF) do?
Shield Therapeutics plc operates as a specialized pharmaceutical firm, dedicated to developing and bringing to market advanced clinical therapies that address significant unfulfilled medical requirements. Its flagship product, Accrufer/Feraccru, offers an innovative, non-salt-based oral treatment specifically for adults suffering from iron defic...
Where does SHIEF trade?
Shield Therapeutics plc (SHIEF) trades on the Other OTC.
What sector is SHIEF in?
Shield Therapeutics plc (SHIEF) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Shield Therapeutics plc?
Anders Lundstrom is the chief executive officer of Shield Therapeutics plc (SHIEF).
Where is Shield Therapeutics plc headquartered?
Shield Therapeutics plc is headquartered in United Kingdom.
Does SHIEF pay a dividend?
Shield Therapeutics plc (SHIEF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SHIEF go public?
Shield Therapeutics plc (SHIEF) completed its initial public offering in 2019.